YX-2-107 (42, Figure 7) could promote the rapid and preferential degradation of CDK6 over CDK4 in Ph+ ALL cells, as well as inhibit the activity of phospho-RB, FOXM1, and proliferation (De Dominici et al., 2020). The gene discussed is CDK6; the disease is acute lymphoblastic leukemia.